Sterling Investment Counsel LLC Boosts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sterling Investment Counsel LLC raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 2,169 shares of the medical research company’s stock after acquiring an additional 207 shares during the quarter. Sterling Investment Counsel LLC’s holdings in Thermo Fisher Scientific were worth $1,342,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of TMO. Signature Resources Capital Management LLC grew its position in Thermo Fisher Scientific by 318.2% during the second quarter. Signature Resources Capital Management LLC now owns 46 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 35 shares during the last quarter. New Millennium Group LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at $29,000. Stephens Consulting LLC raised its position in shares of Thermo Fisher Scientific by 116.0% in the 2nd quarter. Stephens Consulting LLC now owns 54 shares of the medical research company’s stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at about $32,000. Finally, Bank & Trust Co purchased a new position in shares of Thermo Fisher Scientific during the 2nd quarter valued at about $33,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total transaction of $1,201,700.00. Following the sale, the senior vice president now owns 13,083 shares in the company, valued at $7,860,920.55. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $1,201,700.00. Following the transaction, the senior vice president now owns 13,083 shares in the company, valued at approximately $7,860,920.55. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock worth $14,094,292 in the last quarter. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on TMO. UBS Group raised Thermo Fisher Scientific to a “strong-buy” rating in a report on Monday, September 16th. Barclays increased their price target on Thermo Fisher Scientific from $600.00 to $620.00 and gave the stock an “equal weight” rating in a research report on Tuesday, October 15th. Robert W. Baird upped their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Stifel Nicolaus increased their price objective on Thermo Fisher Scientific from $615.00 to $680.00 and gave the company a “buy” rating in a report on Friday, September 20th. Finally, Redburn Atlantic began coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $656.00.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded down $14.50 on Wednesday, hitting $571.88. The stock had a trading volume of 612,009 shares, compared to its average volume of 1,460,783. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The company’s 50 day moving average price is $607.55 and its 200 day moving average price is $584.45. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $627.88. The stock has a market cap of $218.46 billion, a price-to-earnings ratio of 36.37, a P/E/G ratio of 3.85 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.13 by $0.24. The company had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The firm’s quarterly revenue was down 1.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.15 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current year.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.